Increased efficacy of omalizumab in atopic dermatitis patients with wild-type filaggrin status and higher serum levels of phosphatidylcholines.
Allergy
; 69(1): 132-5, 2014 Jan.
Article
in En
| MEDLINE
| ID: mdl-24111531
ABSTRACT
Omalizumab, a monoclonal antibody targeting IgE, is an established therapy for severe allergic asthma and has shown efficacy in chronic spontaneous urticaria. Small-scale studies indicated some beneficial effect also in atopic dermatitis (AD). To evaluate the efficacy of omalizumab in AD and to identify markers associated with treatment response, we conducted a prospective 28-week open-label trial on 20 adults with moderate-to-severe AD. Our results confirm previous observations of a positive response in a subgroup of patients and suggest that responders are characterized by the absence of filaggrin mutations and altered lipid metabolite profiles with high levels of various glycerophospholipids.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Phosphatidylcholines
/
Dermatitis, Atopic
/
Intermediate Filament Proteins
Limits:
Humans
Language:
En
Journal:
Allergy
Year:
2014
Document type:
Article
Affiliation country:
Alemania